Irinotecan Medac

Irinotecan, the active ingredient in Irinotecan Medac, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients and is indicated for use in combination chemotherapy regimens under the supervision of qualified healthcare professionals.

GNH USA supplies Irinotecan Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality and regulatory compliance across all markets and adheres to stringent quality standards.

Irinotecan Medac is used in the treatment of colorectal cancer and related metastatic disease. - Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy. - Advanced colorectal cancer: provides disease control as part of second‑line treatment protocols. - Colorectal adenocarcinoma with metastasis: contributes to tumor shrinkage and symptom relief in combination regimens.

Irinotecan Medac may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate nausea often occurring during or after infusion. - Vomiting: occasional vomiting that may require anti‑emetic support. - Diarrhea: frequent watery stools, typically manageable with loperamide. - Neutropenia: reduced neutrophil count increasing infection risk. - Alopecia: hair thinning or loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenia: profound drop in white blood cells leading to febrile neutropenia. - Febrile neutropenia: fever accompanying neutropenia requiring urgent medical care. - Severe diarrhea/colitis: potentially life‑threatening intestinal inflammation. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases. - Hepatic toxicity: elevated liver enzymes or jaundice. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress.

Prior to initiating Irinotecan Medac, clinicians should evaluate patient-specific factors and monitor for known risks. - Renal function: assess baseline creatinine clearance and adjust monitoring as needed. - Hepatic function: evaluate liver enzymes because impaired metabolism can increase toxicity. - Myelosuppression: perform regular complete blood counts to detect neutropenia early. - Diarrhea: implement prophylactic loperamide and educate patients on early symptom reporting. - Pregnancy: avoid use unless potential benefits outweigh risks, and discuss contraception. - Store at ambient temperature: keep in original container, protect from light and moisture.

Irinotecan Medac can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may raise SN‑38 levels and increase toxicity. - UGT1A1 inhibitors: can reduce SN‑38 clearance leading to severe neutropenia. - Live vaccines: immunosuppression raises risk of infection.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to mucosal damage. - Other myelosuppressive agents: additive bone‑marrow suppression. - Diuretics: potential electrolyte disturbances during severe diarrhea.